Ketamine: to be or not to be

The attempt to support a clinical decision by an adequately powered randomized study is welcome, as palliative medicine needs to have clear information for providing guidelines and recommendations. The conclusion of this trial is that ketamine does not have a clinical benefit when added to opioid in cancer patients with a refractory pain condition (1).